What You Should Know:
– Verily and Lumea today announced a strategic partnership to develop products that can diagnose, prognose, and guide prostate cancer therapy selection with improved objectivity and efficiency.
– Lumea’s integrated digital pathology solution will validate Verily’s AI method for improving cancer detection and grading in partnership with Google Health.
Partnership Goals
The Verily-Lumea collaboration will utilize Lumea’s digital pathology platform and extensive database of pathology cases to enable Verily to validate its Gleason algorithms for prostate cancer developed in partnership with Google Health Integrate Verily’s algorithms into Lumea’s digital pathology platform. Pathologists will then have access to Verily’s AI to assist in identifying and grading prostate cancer within their existing digital workflow
“Verily’s Digital Pathology technologies have the promise to provide more efficient and valuable techniques to democratize access to precision oncology” said Jessica Mega, MD, MPH, Verily Chief Medical & Scientific Officer, Co-Founder. “Lumea’s integrated digital pathology solution was the ideal technology platform for us to validate our artificial intelligence method to improve cancer detection and grading.”
